New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For VVUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
09:28 EDTVVUSVIVUS sales force reduction negative for Qsymia outlook, says RBC Capital
After Vivus announced that it would reduce its sales force to about 100 from about 150, RBC Capital says that the move will hamper the trajectory of the company's anti-obesity drug, Qsymia. The firm says that other companies launching anti-obesity drugs have much larger sales teams. However, it keeps an Outperform rating on VIVUS.
March 30, 2015
16:07 EDTVVUSVIVUS continues talks with U.S., EU over Qsymia
VIVUS announced an operational update, including certain key corporate decisions and plans regarding Qsymia capsules CIV. These plans include further investments in high-value, consumer-focused digital media projects in support of obesity education and Qsymia, and focusing the Qsymia field sales organization of approximately 100 territories on the most productive target areas. Management will continue discussions with U.S. and EU regulatory authorities regarding Qsymia development and potential cost-saving measures related to the planned cardiovascular outcomes trial, or CVOT, and will aim to further improve corporate efficiency and control costs while maintaining and extending the value of avanafil. VIVUS plans to discuss with U.S. regulatory authorities and key consultants potential cost-saving alternatives with respect to the Qsymia CVOT, known as AQCLAIM. The company is also in the process of pursuing approval for Qsymia in the EU and other key countries, as well as new indications in other chronic diseases such as obstructive sleep apnea, or OSA, and type 2 diabetes. VIVUS plans to optimize spending while pursuing these potential objectives.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use